The company is currently working with unnamed pharmaceutical companies and labs, focusing on providing and proving their service rather than establishing their own biological IP. The seed funding round, led by TLV partners, will be used to pursue more partnerships and studies, with the aim of making protein engineering as easy as checking email.
Key takeaways:
- Scala Biodesign, a biotech company, has raised $5.5 million in new funding to focus on making existing or promising drugs more practical by tweaking them one molecule at a time.
- The company uses AI and other tools to predict the 3D structure and behavior of proteins, which can help accelerate the process of engineering therapeutic molecules.
- Scala combines protein structure prediction with clinical data and observations of naturally occurring proteins to produce a system that can identify changes that accomplish a given outcome.
- Currently, Scala is working with some unnamed pharmaceutical companies and labs, and is focusing on providing and proving out their service rather than establishing their own biological IP.